NADAC price lookup: what acquisition-cost data can and cannot say about payer spread

A market-access analyst opens the CMS National Average Drug Acquisition Cost file to estimate how much margin a payer captures between what a pharmacy pays for a drug and what the plan reimburses. The record shows a brand tablet at $19.15 per unit next to a "Corresponding Generic" value of $0.031 — a gap large enough to look like the payer spread the analyst is hunting for. It is not. That gap is the distance between the brand's acquisition cost and the generic's acquisition cost, both measured before rebates, before dispensing fees, before any Maximum Allowable Cost adjustment, and before the 340B or contracted pricing that actually determines what changes hands. NADAC answers a real and useful question — what does a typical retail pharmacy pay to acquire this NDC — but it answers a narrower question than "what is the payer spread," and reading it as the latter is the most common misread in acquisition-cost analysis.

NADAC is the closest thing the United States has to a public, national pharmacy acquisition-cost benchmark, and the June 2026 extract holds 696,293 unit-level pricing records. This article is a reading guide for that file, written for pricing and access, pharmacy operations, Medicaid, and manufacturer market-access teams who use NADAC to benchmark, model, or sanity-check. It covers what each field means, what NADAC can defensibly tell you about generic competition and acquisition cost, and — just as important — what it cannot tell you about rebates, gross-to-net, and the spread a payer actually realizes. It is not reimbursement advice for any specific plan. For the aggregate cost distribution — the most expensive drugs per unit, brand-versus-generic medians, and the biologics tier — see the companion CMS NADAC by the numbers analysis; this article stays on how to read a record and what to avoid concluding from it.

What NADAC actually is: a voluntary invoice-price survey

NADAC is calculated for CMS by the accounting firm Myers and Stauffer through a monthly, voluntary survey of roughly 2,000 to 2,500 retail community pharmacies, drawn from a nationally distributed random sample that includes both chain and independent pharmacies. Pharmacies report what they paid to acquire each drug — the invoice price from their wholesaler — and CMS publishes the average per pricing unit at the 11-digit NDC level, updated weekly and monthly. Two features of the methodology define everything NADAC can and cannot say.

First, the survey captures the invoice price, which deliberately excludes off-invoice discounts, prebates, rebates, and other price concessions. NADAC is the pharmacy's gross acquisition cost before the back-end adjustments that large chains and GPOs negotiate. Second, the survey is voluntary and sample-based, with quality controls that exclude reported prices at or above AWP and trim outliers beyond roughly two standard deviations. The result is a national average, not a contract price; a specific pharmacy's actual acquisition cost may sit above or below it depending on purchasing power and contract terms. Approximately 46 state Medicaid programs use NADAC as a reference when setting pharmacy reimbursement, which is why the file exists at all — it was built to satisfy the Actual Acquisition Cost standard for Medicaid fee-for-service reimbursement, not to be a commercial-net price benchmark.

The fields, in the order an access team reads them

NADAC Per Unit and Pricing Unit — the number and its denominator

The core record is a per-unit price, but the Pricing Unit field is what makes the number comparable. In the June 2026 extract, 81.9% of records are priced per Each (EA), 12.6% per Milliliter (ML), and 5.5% per Gram (GM). The operational rule is that you cannot compare an EA price directly to an ML or GM price — a biologic at a few dollars per milliliter may cost hundreds of dollars per vial once the container volume is applied, and a topical at a low per-gram rate translates to a meaningful per-tube cost only against the package size. Every NADAC comparison must normalize to the same pricing unit before it means anything. Confusing EA and ML is the single most common arithmetic error in acquisition-cost modeling.

Classification for Rate Setting — generic, brand, and the biologicals

The classification field separates generics from brands and flags the subcategories that change interpretation: 92.0% of records are classified G (generic), 7.6% B (brand), 0.3% B-ANDA (a brand product also marketed under an ANDA), and 0.1% B-BIO (biological product). The classification matters because NADAC's behavior differs by class: generics are commodity-priced and move with competition, brands reflect the manufacturer's list-to-pharmacy economics, and biologicals carry the highest per-unit values and the largest brand-to-generic gaps. A rate-setting classification of B-ANDA signals a product whose brand version coexists with an authorized generic, which changes how a payer would set a Maximum Allowable Cost.

Corresponding Generic Drug NADAC Per Unit — the brand-versus-generic acquisition gap

For brand-classified records, NADAC carries an optional Corresponding Generic Drug NADAC Per Unit and effective date — the per-unit acquisition cost of the generic equivalent, where one exists. In the June 2026 extract, 24,133 of the 53,189 brand records carry a corresponding-generic price. This field is where NADAC is most informative about generic competition, but only about acquisition cost, not about payer economics. Worked examples from the extract:

A 623× brand-to-generic acquisition ratio tells a market-access team that the generic is deeply commoditized at the pharmacy-acquisition level and that any payer still reimbursing near the brand price is exposed — but it says nothing about what the brand manufacturer is rebating to keep formulary position, which is where the real gross-to-net story lives. The corresponding-generic field is a competitive-intensity signal, not a net-price signal.

The empty corresponding-generic field — a still-brand product with no acquisition benchmark

The flip side is more important for launch and erosion planning: when the corresponding-generic field is empty on a brand record, NADAC is telling you that, as of these effective dates, no generic acquisition benchmark exists for that product. In the June 2026 extract, ELIQUIS (apixaban) 2.5 mg carries a brand acquisition cost of about $9.69 per tablet, classification B, with an empty corresponding-generic field — meaning NADAC does not yet carry a generic acquisition comparator for it. An access team reading that empty field should not conclude generics are unavailable in the market; it should conclude that the NADAC file, as of these effective dates, does not yet reflect a generic acquisition benchmark, and that any erosion timing or spread model built from this file alone is incomplete for that molecule. The empty field is a data-limitation flag, not a market-status statement.

Effective Date and As of Date — freshness and staleness

Each record carries an Effective Date (when the NADAC price took effect) and an As of Date (the file run). In the June 2026 extract, roughly 89.4% of records carry a 2026 effective date and about 10.6% still carry a 2025 effective date. The staleness tail matters because NADAC is a point-in-time survey: a record with a months-old effective date may not reflect a recent launch, a price increase, or a generic entry. Any acquisition-cost model should carry the effective date alongside the price and should treat records with stale effective dates as provisional until a refreshed NADAC file confirms them.

OTC, Explanation Code, and Pharmacy Type Indicator

Three smaller fields complete the record. The OTC flag separates over-the-counter products (about 61,000 records, or 8.8%, carry Y) from prescription products, which matters because OTC acquisition costs behave differently and are often excluded from pharmacy-benefit modeling. The Explanation Code records why a price was set the way it was (for example, a code indicating the price was derived from a related NDC or a prior period), which is useful when a number looks anomalous. The Pharmacy Type Indicator records the chain-versus-independent split relevant to the price. None of these reveal net economics, but each tells you how much weight to put on a given record.

What NADAC can defensibly tell you

Read for what it is, NADAC supports four legitimate inferences:

• Acquisition-cost benchmarking. A defensible national average of what retail pharmacies pay to acquire a specific NDC, suitable as a reference point for Medicaid AAC and as a sanity check against contract or list prices.
• Brand-versus-generic acquisition gap. The corresponding-generic field quantifies how commoditized the generic has become at acquisition, a real competitive-intensity read.
• Generic erosion trajectory. Tracked across effective dates, NADAC shows generic per-unit acquisition cost falling as entrants accumulate — a generic-competition signal, though again at acquisition cost rather than net.
• Dosage-form and package economics. Normalized to a common pricing unit, NADAC reveals how cost shifts across strength, formulation, and package size, which is useful for formulary and channel analysis.

What NADAC cannot tell you — and why the payer spread is not in this file

The misread to avoid is treating NADAC as a net-price or payer-spread file. It is none of the following:

• It is not reimbursement. What a plan pays a pharmacy is NADAC (or a MAC below it) plus a professional dispensing fee, sometimes less a copay — a separate calculation NADAC does not perform and a number NADAC does not contain. A reimbursement-above-NADAC gap is observable in the data — one Medicaid analysis found roughly 7.5% of fee-for-service prescriptions were reimbursed at least $15 above NADAC in a recent quarter — but that gap is not cleanly the payer spread, because a $10–$15 dispensing fee sits inside it. Confusing the two overstates the margin a payer actually keeps.
• It is not gross-to-net. Manufacturer rebates, chargebacks, and discounts to payers and PBMs are not in NADAC at all. NADAC sits on the pharmacy-acquisition side, before any manufacturer-to-payer concession, so it cannot reproduce net revenue or the spread a payer keeps after rebate.
• It is not 340B or contracted pricing. Safety-net 340B pricing, GPO contracts, and PBM contracted networks all sit below the invoice price NADAC surveys and are invisible to the file.
• It is not AWP, WAC, or list. NADAC is explicitly an acquisition-cost measure, distinct from Average Wholesale Price (a published list benchmark), Wholesale Acquisition Cost (manufacturer list), and invoice-to-pharmacy list; the survey even excludes reported prices at or above AWP. The relationship is roughly stable rather than identical: by CMS's calculation NADAC averages about 5.1% below WAC for brand-name drugs, reflecting the wholesale discount pharmacies negotiate off list. That ratio is useful for translating between benchmarks, but it is an average over brands and does not hold drug-by-drug, so it should not be substituted for the actual NADAC value.
• It does not predict erosion timing. An empty corresponding-generic field means NADAC has no generic benchmark yet; it does not tell you when one will appear or how fast spread will compress.
• It does not show formulary tier or patient cost. Tier placement, step therapy, and copay design are payer constructs absent from the file.

Because the actual payer spread is the gap between what the plan pays the pharmacy (NADAC-derived ingredient cost plus dispensing fee) and what the manufacturer rebates the plan (invisible to NADAC), NADAC alone cannot quantify that spread. It can show you the acquisition-cost half of the equation and flag where a still-brand product lacks a generic comparator; the rebate half must come from elsewhere.

The reading workflow, before quoting a NADAC number

1. Confirm the pricing unit. Normalize EA, ML, and GM to a common basis before any comparison; never compare an EA price to an ML price directly.
2. Read the classification. G, B, B-ANDA, and B-BIO behave differently; a B-ANDA or B-BIO read changes how you would set a MAC or model erosion.
3. Use the corresponding-generic field as a competitive-intensity signal, not a net-price signal. A large ratio means a commoditized generic at acquisition, not a known payer margin.
4. Treat an empty corresponding-generic field as a data limitation, not a market conclusion. Confirm generic status against the Orange Book or Purple Book before modeling erosion from NADAC alone.
5. Carry the effective date with every price. Flag records with stale effective dates as provisional until a refreshed file confirms them.
6. Separate acquisition cost from reimbursement. Add the dispensing fee and apply any MAC before quoting a reimbursement number; never present NADAC as what a plan pays.
7. Acknowledge the rebate blind spot. State explicitly that NADAC cannot reproduce gross-to-net or the post-rebate spread, and source the rebate side separately if the analysis requires it.

What access and pharmacy teams should take from NADAC

For pricing and access teams, NADAC's value is as a public, defensible acquisition-cost anchor that constrains the bottom of any pharmacy-reimbursement model and that surfaces, through the corresponding-generic field, how aggressively a generic has commoditized at the level pharmacies pay. Its limitation is the rebate blind spot: the spread a payer actually realizes sits on the concession side, which no public acquisition-cost file captures, and any model that presents NADAC as the payer spread is misstating the economics. For pharmacy operations and Medicaid teams, NADAC is the reference against which reimbursement adequacy is judged, and reading the effective-date, pricing-unit, and classification fields correctly is what separates a fair benchmark from one that understates a generic's true acquisition cost. And for manufacturer market-access teams, the corresponding-generic and empty-field patterns are early competitive signals worth tracking across file runs — but they are signals about acquisition cost, and the commercial decisions that depend on net economics require the rebate and contract data NADAC structurally cannot provide.

This article is for informational purposes only and does not constitute reimbursement advice, pricing direction for any specific plan, or investment advice. NADAC prices, effective dates, and classifications change with each file run; always verify current records in the CMS NADAC files before relying on a specific value.

Last updated: June 13, 2026.

Sources

• CMS. "Retail Price Survey" (NADAC methodology, weekly/monthly updates, voluntary survey of retail community pharmacies, state use for Actual Acquisition Cost reimbursement). medicaid.gov
• Myers and Stauffer / NCPA. "Summary of Draft Methodology for Calculating NADAC" (survey of 2,000–2,500 pharmacies; 11-digit NDC reporting; invoice price excluding discounts, prebates, and rebates; exclusion of prices at or above AWP; outlier trimming). ncpa.co
• The Ohio State University College of Pharmacy. "Shedding Light on NADAC: How Pricing Power Influences Pharmacy Reimbursement" (NADAC as voluntary monthly invoice-price survey excluding off-invoice concessions; purchasing-power and methodology limitations). pharmacy.osu.edu
• Tich, E. M., et al. "A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses" (NADAC as a pre-rebate payer-cost upper bound; NADAC-to-WAC ratios; distinctness from WAC and federal supply schedule). PMC
• Judi Health. "What Is NADAC and How Does It Differ From AWP?" (NADAC as acquisition cost versus AWP as a published list benchmark; PBM reimbursement implications). judi.health
• Drug Channels Institute. "List Price Reductions Will Deflate the Gross-to-Net Bubble" (NADAC averages about 5.1% below WAC for brands; gross profit as EAC reimbursement minus net acquisition cost; 340B contract-pharmacy economics). drugchannels.net
• KFF. "Costs and Savings Under Federal Policy Approaches to Address Medicaid Prescription Drug Spending" (approximately 7.5% of FFS prescriptions reimbursed at least $15 above NADAC; the gap reflects dispensing fees as well as any PBM spread). kff.org
• CMS. "NADAC Files and Help Desk" (public NADAC files; corresponding generic field; effective and as-of dates; explanation codes). medicaid.gov